Disease · EFO_0010822
stenosing tenosynovitis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. stenosing tenosynovitis. Diseases, record EFO_0010822. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0010822
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- stenosing tenosynovitis
- Open Targets ID
- EFO_0010822
- Other names
- trigger finger
- Highest stage of its drugs
- Phase 3, for 13 of its 15 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs15
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| TRIAMCINOLONE ACETONIDE | CHEMBL1504 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 3 | Drugs and targets |
| TRIAMCINOLONE | CHEMBL1451 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 2 | Drugs and targets |
| BETAMETHASONE | CHEMBL632 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 1 | Drugs and targets |
| DEXAMETHASONE | CHEMBL384467 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 1 | Drugs and targets |
| METHYLPREDNISOLONE | CHEMBL650 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 1 | Drugs and targets |
| BETAMETHASONE DIPROPIONATE | CHEMBL1200384 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 0 | Drugs and targets |
| BETAMETHASONE SODIUM PHOSPHATE | CHEMBL1200762 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 0 | Drugs and targets |
| METHYLPREDNISOLONE ACETATE | CHEMBL1364144 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 0 | Drugs and targets |
| PREDNISOLONE | CHEMBL131 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 0 | Drugs and targets |
| PREDNISONE | CHEMBL635 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 0 | Drugs and targets |
1 to 10 of 15
See all 15 drugsTargets13
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 11 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| PTGS1 | Cyclooxygenase | 1 | Cyclooxygenase inhibitor | Phase 3 | https://conductscience.org/library/genes/5742 | Drugs and targets |
| PTGS2 | Cyclooxygenase | 1 | Cyclooxygenase inhibitor | Phase 3 | https://conductscience.org/library/genes/5743 | Drugs and targets |
| SCN10A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6336 | Drugs and targets |
| SCN11A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/11280 | Drugs and targets |
| SCN1A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6323 | Drugs and targets |
| SCN2A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6326 | Drugs and targets |
| SCN3A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6328 | Drugs and targets |
| SCN4A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6329 | Drugs and targets |
| SCN5A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6331 | Drugs and targets |
1 to 10 of 13
See all 13 targetsTrials10
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02266433 | Dexamethasone Versus Ketorolac Injection for the Treatment of Local Inflammatory Hand and Upper Extremity Disorders | Phase 3 | 245 | 2020-11-02 | DeQuervains Tenosynovitis, Lateral Epicondylitis, Tennis Elbow, Trigger Finger, Tenosynovitis, Inflammatory Disease | DEXAMETHASONE, KETOROLAC | Its record names the disease | ClinicalTrials.gov |
| NCT00951236 | Study Comparing One Versus Two Cortisone Injections for Trigger Finger | Not applicable | 392 | Stenosing Tenosynovitis, Trigger Finger | CORTISONE | Its record names the disease | ClinicalTrials.gov | |
| NCT03131882 | Efficacy of Ultrasound Guided Hyaluronic Injection in Treatment of Trigger Finger | Phase 2/3 | 120 | Trigger Digit | HYALURONIC ACID, TRIAMCINOLONE ACETONIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT04645303 | Injection of Hyaluronic Acid Versus Corticosteroid for Treatment of Trigger Finger | Early phase 1 | 100 | Trigger Finger | HYALURONIC ACID, TRIAMCINOLONE ACETONIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT03914235 | Anesthesia Tumescent for Surgical Management of Tenosynovitis. | Not applicable | 60 | Tenosynovitis | LIDOCAINE | Its record names the disease | ClinicalTrials.gov | |
| NCT06532318 | Comparative Study Between Platelet Rich Plasma and Steroid Injection in Trigger Finger Treatment | Phase 3 | 40 | Trigger Finger Disorder | METHYLPREDNISOLONE | Its record names the disease | ClinicalTrials.gov | |
| NCT06785935 | Comparison Between 2 Treatment Modalities of Trigger Finger: Ultrasound-guided Percutaneous Release of A1 Pulley by a Needle Knife Versus Ultrasound-guided Corticosteroid Injection in the Treatment of Trigger Finger | Not applicable | 40 | Trigger Finger | BETAMETHASONE | Its record names the disease | ClinicalTrials.gov | |
| NCT06288685 | Percutaneous Trigger Finger Release Concomitant Steroid Injection Versus Percutaneous Trigger Finger Release Alone | Phase 3 | 38 | Trigger Finger, Percutaneous A1 Pulley Release, Steroid Injection, Postoperative Pain | TRIAMCINOLONE | Its record names the disease | ClinicalTrials.gov | |
| NCT01950793 | A Comparison Between Sonoguided Injection Corticosteroid and Hyaluronic Acid Injection in Treatment of Trigger Finger | Not applicable | 36 | Trigger Finger | HYALURONIC ACID, TRIAMCINOLONE ACETONIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT04253457 | The SToICAL Study - The Soft Tissue Injection of Corticosteroid And Local Anaesthetic Study | Phase 3 | 25 | Carpal Tunnel Syndrome, De Quervains Tenosynovitis, Trigger Finger | LIDOCAINE, TRIAMCINOLONE | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials2
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Arm Receiving Dexamethasone Injection vs Arm Receiving Ketorolac Injection: deaths from any cause | 0 of 127 | 0 of 118 | 245 | NCT02266433 | Trial comparisons |
| Arm Receiving Dexamethasone Injection vs Arm Receiving Ketorolac Injection: serious adverse events | 0 of 127 | 0 of 118 | 245 | NCT02266433 | Trial comparisons |
Papers from its trials2
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_0010822
GET https://conductscience.org/api/diseases/v1/EFO_0010822/drugs